A 20 gene model for predicting nodal involvement in bladder cancer patients with muscle invasive tumors

PLoS Currents

Volumn , Issue , 2011, Pages

  Dancik, Garrett ^a   Aisner, Dara ^b   Theodorescu, Dan ^c  

^a UNIVERSITY OF COLORADO   (United States)

^b UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

^c University of Colorado Cancer Center   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT;

ARTICLE; BLADDER CANCER; CANCER CHEMOTHERAPY; CANCER INVASION; CANCER RISK; CANCER SURVIVAL; CLINICAL DECISION MAKING; CYSTECTOMY; GENE EXPRESSION; HUMAN; LYMPH NODE METASTASIS; MUSCLE CANCER; MUSCLE INVASIVE TUMOR; PRACTICE GUIDELINE; PREDICTION; PREOPERATIVE PERIOD; RELIABILITY; UNITED STATES; VALIDITY; ADJUVANT THERAPY; CANCER GROWTH; META ANALYSIS (TOPIC); MICROARRAY ANALYSIS; MULTICENTER STUDY (TOPIC); MUSCLE TUMOR; PHASE 3 CLINICAL TRIAL (TOPIC); RANDOMIZED CONTROLLED TRIAL (TOPIC); REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SYSTEMATIC REVIEW (TOPIC);

EID: 84867471622     PISSN: None     EISSN: 21573999     Source Type: Journal    
DOI: 10.1371/currents.RRN1248     Document Type: Article

References (21)

1. Jacobs BL, Lee CT, Montie JE (2010) Bladder Cancer in 2010 How Far Have We Come? Ca-a Cancer Journal for Clinicians 60: 244-272.
2. Jemal A, Siegel R, Xu J, Ward E (2010) Cancer statistics, 2010. CA Cancer J Clin 60: 277-300.
3. Stein JP, Lieskovsky G, Cote R, Groshen S, Feng AC, et al. (2001) Radical cystectomy in the treatment of invasive bladder cancer: long-term results in 1,054 patients. J Clin Oncol 19: 666-675.
4. Grossman HB, Natale RB, Tangen CM, Speights VO, Vogelzang NJ, et al. (2003) Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer. N Engl J Med 349: 859-866.
5. Hall RR (2002) Updated results of a randomized trial of neoadjuvant cisplatin (C) methotrexate (M) and vinblastine (V) chemotherapy for muscle-invasive bladder cancer. Proc Am Soc Clin Oncol 21: 178a (ab 710).
6. Advanced Bladder Cancer Meta-analysis Collaboration (2005). Neoadjuvant chemotherapy in invasive bladder cancer: update of a systematic review and meta-analysis of individual patient data advanced bladder cancer (ABC) meta-analysis collaboration. Eur Urol 48: 202-205; discussion 205-206.
7. Advanced Bladder Cancer Meta-analysis Collaboration (2005). Neoadjuvant chemotherapy for invasive bladder cancer. Cochrane Database Syst Rev: CD005246.
8. Stenzl A, Cowan NC, De Santis M, Kuczyk MA, Merseburger AS, et al. (2011) Treatment of Muscle-invasive and Metastatic Bladder Cancer: Update of the EAU Guidelines. Eur Urol.
9. David KA, Milowsky MI, Ritchey J, Carroll PR, Nanus DM (2007) Low incidence of perioperative chemotherapy for stage III bladder cancer 1998 to 2003: A report from the National Cancer Data Base. Journal of Urology 178: 451-454.
10. Stenzl A, Cowan NC, De Santis M, Jakse G, Kuczyk MA, et al. (2009) The updated EAU guidelines on muscleinvasive and metastatic bladder cancer. Eur Urol 55: 815-825.
11. Cronin M, Sangli C, Liu ML, Pho M, Dutta D, et al. (2007) Analytical validation of the oncotype DX genomic diagnostic test for recurrence prognosis and therapeutic response prediction in node-negative, estrogen receptor-positive breast cancer. Clinical Chemistry 53: 1084-1091.
12. Rosenfeld N, Aharonov R, Meiri E, Rosenwald S, Spector Y, et al. (2008) MicroRNAs accurately identify cancer tissue origin. Nature Biotechnology 26: 462-469.
13. Ma XJ, Patel R, Wang XQ, Salunga R, Murage J, et al. (2006) Molecular classification of human cancers using a 92-gene real-time quantitative polymerase chain reaction assay. Archives of Pathology & Laboratory Medicine 130: 465-473.
14. Buyse M, Loi S, van't Veer L, Viale G, Delorenzi M, et al. (2006) Validation and clinical utility of a 70-gene prognostic signature for women with node-negative breast cancer. Journal of the National Cancer Institute 98: 1183-1192.
15. Pillai R, Deeter R, Rigl CT, Nystrom JS, Miller MH, et al. (2011) Validation and Reproducibility of a MicroarrayBased Gene Expression Test for Tumor Identification in Formalin-Fixed, Paraffin-Embedded Specimens. Journal of Molecular Diagnostics 13: 48-56.
16. National Comprehensvie Cancer Network. Bladder cancer including upper tract tumors and urothelial carcinoma of the prostate. Accessed April 25. http://www.nccn.org/professionals/physician_gls/f_guidelines.asp [subscription required]
17. Smith SC, Baras AS, Dancik G, Ru Y, Ding KF, et al. (2011) A 20-gene model for molecular nodal staging of bladder cancer: development and prospective assessment. Lancet Oncol 12: 137-143.
18. Shi LM, Reid LH, Jones WD, Shippy R, Warrington JA, et al. (2006) The MicroArray Quality Control (MAQC) project shows interand intraplatform reproducibility of gene expression measurements. Nature Biotechnology 24: 1151-1161.
19. Sanchez-Carbayo M, Socci ND, Lozano J, Saint F, Cordon-Cardo C (2006) Defining molecular profiles of poor outcome in patients with invasive bladder cancer using oligonucleotide microarrays. J Clin Oncol 24: 778-789.
20. Lehmann J, Retz M, Wiemers C, Beck J, Thuroff J, et al. (2005) Adjuvant cisplatin plus methotrexate versus methotrexate, vinblastine, epirubicin, and cisplatin in locally advanced bladder cancer: results of a randomized, multicenter, phase III trial (AUO-AB 05/95). J Clin Oncol 23: 4963-4974.
21. Pillai R, Deeter R, Rigl CT, Nystrom JS, Miller MH, et al. (2011) Validation and Reproducibility of a MicroarrayBased Gene Expression Test for Tumor Identification in Formalin-Fixed, Paraffin-Embedded Specimens. Journal of Molecular Diagnostics 13: 48-56.